Research programme: cathepsin K inhibitors - Medivir

Drug Profile

Research programme: cathepsin K inhibitors - Medivir

Alternative Names: CK inhibitors - Medivir; MIV-710; MV074840; MV074942; MV076159

Latest Information Update: 01 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Class Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bone metastases; Osteoarthritis; Osteoporosis
  • Research Rheumatoid arthritis

Most Recent Events

  • 31 Mar 2011 Preclinical development in Osteoarthritis, Osteoporosis and Bone metastases is ongoing
  • 15 Sep 2009 Preclinical trials in Osteoporosis in Sweden (PO)
  • 15 Sep 2009 Pharmacodynamics and adverse events data from a preclinical trial in Osteoporosis presented at the 31st Annual Meeting of The American Society for Bone and Mineral Research (ASBMR-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top